Allarity Therapeutics (ALLR) vs Seres Therapeutics (MCRB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Seres Therapeutics is the larger company by market cap ($12.6 million vs $12.6 million), about 1.0 times the size. Seres Therapeutics converts more of its revenue into profit, with a net margin of 721.9% versus -3509.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALLR | MCRB |
|---|---|---|
| Share price | $0.785 | $1.24 |
| Market cap | $12.56M | $12.64M |
| 1-day change | -9.25% | -6.77% |
| YTD return | -27.31% | — |
| 1-year return | -25.94% | — |
| EPS (TTM) | $-0.79 | $-5.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $320.00K | $789.00K |
| Net income (latest FY) | $-11.23M | $5.70M |
| Operating margin | -3939.06% | -11910.14% |
| Net margin | -3509.69% | 721.93% |
| 52-week high | $1.84 | $18.86 |
| 52-week low | $0.769 | $1.20 |
| Distance from 52-week high | -57.34% | -93.43% |
| Analyst consensus | none | none |
| Avg. price target upside | +1301.27% | +1270.97% |
| Average volume | 131.74K | 74.83K |
| Shares outstanding | 16.00M | 10.20M |
| Employees | 7 | 66 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Seres Therapeutics is more profitable, keeping 721.9 cents of every revenue dollar as net income versus -3509.7 cents for Allarity Therapeutics.
About Allarity Therapeutics
ALLR stock →Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
About Seres Therapeutics
MCRB stock →Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation.
Health Care · Biotechnology: Pharmaceutical Preparations · 66 employees
ALLR vs MCRB FAQ
Which is bigger, Allarity Therapeutics or Seres Therapeutics?
Seres Therapeutics (MCRB) is larger, with a market capitalization of $12.64M compared with $12.56M for Allarity Therapeutics (ALLR).
Are Allarity Therapeutics and Seres Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.